AU2003293807A1 - Mhc class i restricted t-cell stimulating peptides from hepatitis b virus - Google Patents

Mhc class i restricted t-cell stimulating peptides from hepatitis b virus

Info

Publication number: AU2003293807A1
Authority: AU; Australia
Prior art keywords: hepatitis; virus; restricted; mhc class; cell stimulating
Prior art date: 2002-12-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003293807A

Inventor

Bernard Castelein

Johan Desmet

Ignace Lasters

Toon Stegmann

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Algonomics NV

Original Assignee

Algonomics NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-24

Filing date

2003-12-09

Publication date

2004-07-22

2003-12-09 Application filed by Algonomics NV filed Critical Algonomics NV

2004-07-22 Publication of AU2003293807A1 publication Critical patent/AU2003293807A1/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

AU2003293807A 2002-12-24 2003-12-09 Mhc class i restricted t-cell stimulating peptides from hepatitis b virus Abandoned AU2003293807A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP02447276.3		2002-12-24
EP02447276		2002-12-24
PCT/EP2003/013948 WO2004058807A2 (en)	2002-12-24	2003-12-09	Mhc class i restricted t-cell stimulating peptides from hepatitis b virus

Publications (1)

Publication Number	Publication Date
AU2003293807A1 true AU2003293807A1 (en)	2004-07-22

Family

ID=32668936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003293807A Abandoned AU2003293807A1 (en)	2002-12-24	2003-12-09	Mhc class i restricted t-cell stimulating peptides from hepatitis b virus

Country Status (2)

Country	Link
AU (1)	AU2003293807A1 (en)
WO (1)	WO2004058807A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102796172B (en) *	2011-05-23	2015-03-25	中国科学院微生物研究所	Hepatitis B virus (HBV) specific human leukocyte antigen-A33 (HLA-A33) restrictive epitope peptides and application thereof
US9133241B2 (en)	2013-10-11	2015-09-15	Tarix Pharmaceuticals Ltd.	Peptide compositions
BR112016007816A2 (en) *	2013-10-11	2017-12-05	Tarix Pharmaceuticals Ltd	innovative peptide compositions
WO2015130488A2 (en) *	2014-02-28	2015-09-03	Immunotope, Inc.	Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
EP3181146A1 (en) *	2015-12-16	2017-06-21	Ruprecht-Karls-Universität Heidelberg	Cyclic ntcp-targeting peptides and their uses as entry inhibitors
KR102234027B1 (en) *	2018-05-09	2021-03-31	서울대학교산학협력단	Hepatitis b virus-derived polypeptide and use thereof
KR102711471B1 (en) *	2020-08-14	2024-09-30	서울대학교산학협력단	A pharmaceutical composition for preventing or treating cancer comprising hepatitis b virus-derived polypeptide
CN114591404B (en) *	2022-03-23	2024-12-10	成都朗谷生物科技股份有限公司	Hepatitis B virus antigen peptide suitable for individuals with leukocyte antigen haplotype HLA-A2 and its application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL86832A (en) *	1987-06-22	2002-09-12	Medeva Holdings Bv	Recombinant dna molecule including the nucleotide sequence of part of the hbv pre-s1 coding region, an immunogenic particle containing plurality of monomers of a peptide containing pre-s1 epitope and pharmaceutical compositions containing the same
US5780036A (en) *	1991-08-26	1998-07-14	The Scripps Research Institute	Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
WO1994020127A1 (en) *	1993-03-05	1994-09-15	Cytel Corporation	Hla-a2.1 binding peptides and their uses
CN1454082A (en) *	2000-09-08	2003-11-05	艾普免疫公司	inducing cellular immune response against hepatitis B virus using peptide and nucleic acid compositions

2003
- 2003-12-09 AU AU2003293807A patent/AU2003293807A1/en not_active Abandoned
- 2003-12-09 WO PCT/EP2003/013948 patent/WO2004058807A2/en not_active Ceased

Also Published As

Publication number	Publication date
WO2004058807A3 (en)	2004-09-30
WO2004058807A2 (en)	2004-07-15

Publication	Publication Date	Title
PL371007A1 (en)	2005-06-13	Macrocyclic peptides active against the hepatitis c virus
IL174403A0 (en)	2006-08-01	Macrocyclic peptides active against the hepatitis c virus
PT1505963E (en)	2011-06-28	Hepatitis c virus inhibitors
AU3328900A (en)	2000-10-23	Influenza virus hemagglutinin-binding peptides
AU2003206862A1 (en)	2003-09-02	Hepatitis b vaccines
PL376967A1 (en)	2006-01-23	Vaccine against hcv
AU2003301850A1 (en)	2004-06-07	Hiv vaccine
AU2003282498A1 (en)	2004-05-04	Hiv vaccine formulations
AU2003294757A1 (en)	2004-06-23	Formulations useful against hepatitis c virus infections
AU2003300831A1 (en)	2004-06-30	Recombinant vaccine against flavivirus infection
AU2003278063A1 (en)	2004-05-04	Mhc multimers
AU2003293807A1 (en)	2004-07-22	Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
AU2003289603A1 (en)	2004-07-09	Tumor vaccine
AU2003228863A1 (en)	2003-11-17	Immunogenic peptides
AU2003274470A1 (en)	2004-05-25	Vacuum auto-retractable safety syringe
AU2003301865A1 (en)	2004-06-07	Epitopes of hepatitis c virus
AU2002952524A0 (en)	2002-11-21	Epstein barr virus peptide epitopes
AU2003273035A1 (en)	2004-05-04	Gene vaccine
AU2003230790A1 (en)	2003-10-20	Hepatitis c virus sub-genomic replicons
AU2003221569A1 (en)	2003-10-20	Cd4+ t-lymphocyte-specific hepatitis c virus epitopes
AU4957800A (en)	2000-12-18	Vaccine against isa virus
AU2003256404A1 (en)	2004-02-25	Hepatitis c virus assays
GB0225736D0 (en)	2002-12-11	T-Cell Independent Vaccine
AU2003225479A1 (en)	2003-11-10	Reporter-selectable hepatitis c virus replicon
AUPS084502A0 (en)	2002-03-28	Anti-protozoal vaccine

Legal Events

Date	Code	Title	Description
2005-09-08	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase